Abstract
Cannabinoids have been reported to alter the activities of immune cells in vitro and in vivo. These compounds may serve as ideal agents for adjunct treatment of pathological processes that have a neuroinflammatory component. As highly lipophilic molecules, they readily access the brain. Furthermore, they have relatively low toxicity and can be engineered to selectively target cannabinoid receptors. To date, two cannabinoid receptors have been identified, characterized and designated CB1 and CB2. CB1 appears to be constitutively expressed within the CNS while CB2 apparently is induced during inflammation. The inducible nature of expression of CB2 extends to microglia, the resident macrophages of the brain that play a critical role during early stages of inflammation in that compartment. Thus, the cannabinoid-cannabinoid receptor system may prove therapeutically manageable in ablating neuropathogenic disorders such as Alzheimers disease, multiple sclerosis, amyotrophic lateral sclerosis, HIV encephalitis, closed head injury, and granulomatous amebic encephalitis.
Keywords: Alzheimer's, amyotrophic lateral sclerosis, cannabinoids, cannabinoid receptors, granulomatous amebic encephalitis, HIV encephalitis, multiple sclerosis, neuroinflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Volume: 8 Issue: 3
Author(s): G. A. Cabral and L. Griffin-Thomas
Affiliation:
Keywords: Alzheimer's, amyotrophic lateral sclerosis, cannabinoids, cannabinoid receptors, granulomatous amebic encephalitis, HIV encephalitis, multiple sclerosis, neuroinflammation
Abstract: Cannabinoids have been reported to alter the activities of immune cells in vitro and in vivo. These compounds may serve as ideal agents for adjunct treatment of pathological processes that have a neuroinflammatory component. As highly lipophilic molecules, they readily access the brain. Furthermore, they have relatively low toxicity and can be engineered to selectively target cannabinoid receptors. To date, two cannabinoid receptors have been identified, characterized and designated CB1 and CB2. CB1 appears to be constitutively expressed within the CNS while CB2 apparently is induced during inflammation. The inducible nature of expression of CB2 extends to microglia, the resident macrophages of the brain that play a critical role during early stages of inflammation in that compartment. Thus, the cannabinoid-cannabinoid receptor system may prove therapeutically manageable in ablating neuropathogenic disorders such as Alzheimers disease, multiple sclerosis, amyotrophic lateral sclerosis, HIV encephalitis, closed head injury, and granulomatous amebic encephalitis.
Export Options
About this article
Cite this article as:
Cabral A. G. and Griffin-Thomas L., Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/187153008785700118
DOI https://dx.doi.org/10.2174/187153008785700118 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets Current Breakthroughs in Structure-based Design of Synthetic and Natural Sourced Inhibitors Against Zika Viral Targets
Current Topics in Medicinal Chemistry Novel Targets for the Development of Anti-Herpes Compounds
Infectious Disorders - Drug Targets Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets The Causes and Consequences of Childhood Encephalitis in Asia
Infectious Disorders - Drug Targets Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy Human Evolution, Life History Theory, and the End of Biological Reproduction
Current Aging Science An Update on the Bananins: Anti-RNA-Viral Agents with Unique Structural Signature
Anti-Infective Agents Microbiota Regulation of Inflammatory Bowel Disease
Inflammation & Allergy - Drug Targets (Discontinued) Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Alzheimers Disease: From Pathogenesis to Disease-Modifying Approaches
CNS & Neurological Disorders - Drug Targets Immunization for Persons Infected with Human Immunodeficiency Virus
Current HIV Research Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research New Opportunities in the Structure-based Design of Anti-Protozoan Agents
Current Topics in Medicinal Chemistry Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery The Effects of Psychopharmacologic and Therapeutic Approaches on Neuro-imaging in Obsessive-compulsive Disorder
Current Neuropharmacology